Trevena Inc. (TRVN)’s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN) – The Broch Herald

Trevena Inc. (NASDAQ:TRVN) and VistaGen Therapeutics Inc. (NASDAQ:VTGN), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Earnings and Valuation

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Trevena Inc. and VistaGen Therapeutics Inc.

Profitability

Table 2 provides us the net margins, return on assets and return on equity of both companies.

Volatility and Risk

Trevena Inc.s current beta is 2.39 and it happens to be 139.00% more volatile than S&P 500. From a competition point of view, VistaGen Therapeutics Inc. has a -0.48 beta which is 148.00% less volatile compared to S&P 500.

Liquidity

The Current Ratio and a Quick Ratio of Trevena Inc. are 3.6 and 3.6. Competitively, VistaGen Therapeutics Inc. has 4.9 and 4.9 for Current and Quick Ratio. VistaGen Therapeutics Inc.s better ability to pay short and long-term obligations than Trevena Inc.

Analyst Recommendations

The table delivered features the ratings and recommendations for Trevena Inc. and VistaGen Therapeutics Inc.

Trevena Inc.s upside potential currently stands at 394.84% and an $3.5 average target price. Competitively VistaGen Therapeutics Inc. has an average target price of $22, with potential upside of 4,957.47%. The results from earlier shows that analysts opinion suggest that VistaGen Therapeutics Inc. seems more appealing than Trevena Inc.

Institutional & Insider Ownership

The shares of both Trevena Inc. and VistaGen Therapeutics Inc. are owned by institutional investors at 32.2% and 20.4% respectively. 1% are Trevena Inc.s share owned by insiders. Competitively, VistaGen Therapeutics Inc. has 0.2% of its share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Trevena Inc. has 120.93% stronger performance while VistaGen Therapeutics Inc. has -66% weaker performance.

Summary

On 8 of the 11 factors Trevena Inc. beats VistaGen Therapeutics Inc.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a -receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

See the rest here:
Trevena Inc. (TRVN)'s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN) - The Broch Herald